Baillie Gifford Worldwide Health Innovation Fund Class A Fonds
6,87
EUR
+0,03
EUR
+0,43
%
NAV
Werbung
Anlageziel
The investment objective of the Fund is to provide strong returns over the long term by investing primarily in a global equity portfolio selected from companies engaged in the healthcare industry and that promotes better healthcare outcomes by driving real change for patients and the healthcare system and evidence care about patients. The Fund may also invest in other transferable securities, money market instruments, cash and cash equivalents.
Stammdaten
Name | Baillie Gifford Worldwide Health Innovation Fund Class A EUR Acc Fonds |
ISIN | IE00BN7HTK74 |
WKN | |
Fondsgesellschaft | Baillie Gifford Investment Management (Europe) Limited |
Benchmark | MSCI ACWI/Health Care |
Ausschüttungsart | Thesaurierend |
Manager | Julia Angeles, Marina Record, Rose Nguyen |
Domizil | Ireland |
Fondskategorie | Aktien |
Auflagedatum | 29.10.2020 |
Geschäftsjahr | 30.09. |
VL-fähig? | Nein |
Depotbank | Brown Brothers Harriman Trustee Services (Ireland) Limited |
Zahlstelle | UBS Switzerland AG |
Riester Fonds | Nein |
Basisdaten
Auflagedatum | 29.10.2020 |
Depotbank | Brown Brothers Harriman Trustee Services (Ireland) Limited |
Zahlstelle | UBS Switzerland AG |
Domizil | Ireland |
Geschäftsjahr | 30.09. |
Aktuelle Daten
Morningstar Rating | |
Aktueller Rücknahmepreis | 6,87 |
Anzahl Fonds der Kategorie | 817 |
Volumen der Tranche | 445.391,66 EUR |
Fondsvolumen | 20,82 Mio. EUR |
Total Expense Ratio (TER) | 1,65 |
Gebühren
Laufende Kosten | 1,86% |
Total Expense Ratio (Verwaltungsgebühren & sonst. Kosten) | 1,65% |
Transaktionskosten | 0,21% |
Depotbankgebühr | - |
Managementgebühr | 1,50% |
Rücknahmegebühr | - |
Ausgabeaufschlag | 5,00% |
Performancedaten
Veränderung Vortag | 0,03 |
WE seit Jahresbeginn |